知镜 Cognispect · 医学文献与研究工作台

M1 macrophage-derived exosomes aggravate diabetic nephropathy by regulating the WTAP/S1PR2 axis.

Li L, Liu H, Mao Y, Wang H, Song L, Kang Z.
Journal of diabetes investigation · 2026-09-26 · PMID 42798279

文献摘要

Background Diabetic nephropathy (DN) is a severe microvascular complication of diabetes mellitus. The specific role of M1 macrophage-derived exosomes in DN progression remains largely unexplored. Methods THP-1 monocytes were differentiated into M0 macrophages and polarized into M1 macrophages for exosome extraction. WTAP was silenced using shRNA to generate WTAP-deficient exosomes. Glomerular endothelial cells (GECs) were exposed to high glucose (HG) and co-incubated with modified exosomes. Cell viability, oxidative stress, apoptosis, barrier function, and angiogenic capacity were assessed. The WTAP-S1PR2 interaction was validated by RIP, MeRIP, and dual-luciferase assays. In vivo, db/db mice received tail vein injections of respective exosomes for 8 weeks, followed by assessments of renal function, histopathology, and inflammation. Results M1 exosomes were internalized by GECs. WTAP delivered by shNC/M1-Exo bound S1PR2 mRNA, enhancing its m6A modification and stability, thereby activating the RhoA/ROCK1 axis and aggravating HG-induced GEC injury, oxidative stress, apoptosis, and endothelial permeability. Conversely, shWTAP/M1-Exo attenuated these effects, and S1PR2 overexpression reversed the protective effects. In vivo, shWTAP/M1-Exo improved renal function, ameliorated histopathological damage and fibrosis, and reduced systemic inflammation in db/db mice. Conclusion M1 macrophage-derived exosomes promote DN progression by delivering WTAP to stabilize S1PR2 mRNA in an m6A-dependent manner. Engineered exosomes lacking WTAP represent a promising targeted nanomedicine strategy for DN treatment.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。